| Name | Title | Contact Details |
|---|
In 2007 the Delaware Health Information Network (DHIN) became the first live, statewide health information network in the nation. DHIN currently serves: - 100% of Delaware’s acute care hospitals - 100% of Delaware’s long term care and skilled nursing facilities - Approaching 100% of medical providers who have enrolled and are participating in DHIN More than 14,000,000 clinical results and reports are posted on DHIN each year – and the total patient records in the system now exceed 2,100,000, featuring patient records from all 50 states. In the six years that DHIN has been active, the system has proven its reliability and worth to hospitals, medical professionals and patients throughout Delaware. DHIN securely delivers fast and accurate patient information from hospitals, laboratories, and radiology facilities directly to doctors’ offices. DHIN makes it possible to deliver higher quality medical care more quickly, and at a lower cost, using a federated data model for medical records, aggregating those records and eliminating the manual transmittal of medical data. Frequent audits confirm that the system is secure and that data is used properly. The Delaware Health Information Network (DHIN) was enacted by the Delaware General Assembly in 1997 as a public-private partnership for the benefit of all citizens of Delaware to advance the creation of a statewide health information network and to address Delaware`s needs for timely, reliable and relevant health care information.
Professional Dynamics is a Folsom, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Shape Up The Nation is the first corporate wellness company focused on leveraging the power of trusted social networks to promote healthy living.
Lexicomm International, Ltd. is a Jenkintown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.